FTSE 100 news / Companies and sectors / GSK / 19 October 2026

GSK (GSK): news on Monday 19 October 2026

+8.5 strongly positive

Coverage was mainly about positive early-stage lung cancer data for Ris-Rez, with a 61% response rate reported. Commentary on results beating forecasts and the shares looking undervalued added to the positive lean.

What drove it

Ris-Rez lung cancer data
results beat forecasts
valuation commentary

The 7 stories

Each headline's own score, strongest first. Links go to the publisher.

+10.0 GSK lung cancer drug shows 61% response rate in early global trial Proactive financial news
Strong 61% response rate in early lung cancer trial.
+9.7 GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial TradingView
Reports 61% overall response rate in Phase IB trial.
+9.2 REG - GSK PLC - Ris-Rez positive early data in lung cancer TradingView
Company announcement of positive early lung cancer data.
+8.0 Blue-Chip Stock GSK (LSE:GSK) Beats Forecasts And Launches Efficiency Drive: What It Means Kalkine Media
Results beat forecasts and efficiency drive launched.
+6.0 GSK (LSE:GSK) Stock Looks Undervalued On Its 59% Five Year Run Simply Wall Street
Valuation piece calls shares undervalued after strong five-year run.
+1.3 Alina Gruber Starts a New Role in Global Medical Affairs Oncology at GSK Oncodaily
Minor senior hire in oncology medical affairs.
+0.5 GSK stock pre-market at EUR 22.20: drugmaker ahead of Xetra open - ad-hoc-news.de ad-hoc-news.de
Routine pre-market price note, essentially factual.

GSK: every day · Pharma and healthcare on 19 October 2026 · FTSE 100 overview for the day